CSF RT-QuIC Has High Diagnostic Specificity, Sensitivity for Prions

Share this content:
CSF RT-QuIC Has High Diagnostic Specificity, Sensitivity for Prions
CSF RT-QuIC Has High Diagnostic Specificity, Sensitivity for Prions

FRIDAY, Dec. 2, 2016 (HealthDay News) -- Cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) has high diagnostic specificity and sensitivity for prion diseases, according to a study published online Nov. 28 in the Annals of Neurology.

Aaron Foutz, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues performed CSF RT-QuIC in 2,141 patients with rapidly progressive neurologic disorders. In 272 cases that were autopsied, the authors determined diagnostic sensitivity and specificity, and assessed the impact of mutations and polymorphisms in the PRNP gene.

The researchers found that CSF RT-QuIC had diagnostic specificity and sensitivity of 98.5 and 92 percent, respectively, in a blinded retrospective analysis, which matched the 100 percent sensitivity and 95 percent specificity of a blind prospective study. The CSF RT-QuIC differentiated 94 percent of cases of sporadic Creutzfeldt-Jakob disease (sCJD) MM1 from MM2 phenotype, and 80 percent of sCJD VV2 from VV1. Intermediate CSF RT-QuIC patterns were generated with the mixed prion type 1-2 and cases heterozygous for codon 129, while distinct profiles for each PRNP gene mutation were seen for genetic prion diseases.

"The diagnostic performance of the improved CSF RT-QuIC is superior to surrogate marker tests for prion diseases such as 14-3-3 and Tau proteins, and together with PRNP gene sequencing, the test allows the major prion subtypes to be differentiated in vivo," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »